A J Kazimi bought $1,827 of CPIX
Chairman and CEO at CUMBERLAND PHARMACEUTICALS INC. 1,426 shares at an average of $1.28, traded Oct 1, 2024, filed Nov 5, 2024.
Score components
- +25RoleCEO
- 0Trade size$2k at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m 0.0%, 3m +218.6%, 6m +273.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-24-045329, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.27 | $79 | 5,698,657 | Nov 5, 2024 |
| Oct 2, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.29 | $80 | 5,698,719 | Nov 5, 2024 |
| Oct 3, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.28 | $79 | 5,698,781 | Nov 5, 2024 |
| Oct 4, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.28 | $79 | 5,698,843 | Nov 5, 2024 |
| Oct 7, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.29 | $80 | 5,698,905 | Nov 5, 2024 |
| Oct 8, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.30 | $81 | 5,698,967 | Nov 5, 2024 |
| Oct 9, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.31 | $81 | 5,699,029 | Nov 5, 2024 |
| Oct 10, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.32 | $82 | 5,699,091 | Nov 5, 2024 |
| Oct 11, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.39 | $86 | 5,699,153 | Nov 5, 2024 |
| Oct 14, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.37 | $85 | 5,699,215 | Nov 5, 2024 |
| Oct 15, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.30 | $81 | 5,699,277 | Nov 5, 2024 |
| Oct 16, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.25 | $78 | 5,699,339 | Nov 5, 2024 |
| Oct 17, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.30 | $81 | 5,699,401 | Nov 5, 2024 |
| Oct 18, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.28 | $79 | 5,699,463 | Nov 5, 2024 |
| Oct 21, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.25 | $78 | 5,699,525 | Nov 5, 2024 |
| Oct 22, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.25 | $78 | 5,699,587 | Nov 5, 2024 |
| Oct 23, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.26 | $78 | 5,699,649 | Nov 5, 2024 |
| Oct 24, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.24 | $77 | 5,699,711 | Nov 5, 2024 |
| Oct 25, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.23 | $76 | 5,699,773 | Nov 5, 2024 |
| Oct 28, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.25 | $78 | 5,699,835 | Nov 5, 2024 |
| Oct 29, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.24 | $77 | 5,699,897 | Nov 5, 2024 |
| Oct 30, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.32 | $82 | 5,699,959 | Nov 5, 2024 |
| Oct 31, 2024 | POpen-market purchase Common Stock10b5-1 | +62 | $1.20 | $74 | 5,700,021 | Nov 5, 2024 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $858 168 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $429 84 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $858 168 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,824 945 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,635 1,035 shares | +0% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $833 186 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $833 186 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $417 93 shares | +0% | |
| 14Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,548 875 shares | +0% | |
| 24Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $881 168 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.